Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q4 2018 · 10-K
Revenue$2.01M$2.01M−68.4% vs Q4 2017 Net Income-$22.53M-$22.53MN/M vs Q4 2017 EPS Diluted-$0.70-$0.70N/M vs Q4 2017 Operating Income-$23,161,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,871,000N/M Margins · derivedOperating margin-1153.4%−958.9 pt vs Q4 2017
Net margin-1122.1%−935.7 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 26, 2019 · 57 d after period end